European regulators have greenlit a twice-yearly injection to prevent HIV that has been hailed as a game-changer in the course of the epidemic.
The jab from the drugmaker Gilead was considered one of the biggest medical breakthroughs of 2024, offering an alternative to daily pills. The drug, called lenacapavir, was 100 per cent effective at preventing the virus in clinical studies.
